Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

This trial is testing a new treatment sequence for people with head and neck squamous cell carcinoma that has come back or spread. It involves an initial combination chemotherapy regimen (TPEx) followed by maintenance therapy with two immunotherapy drugs, avelumab and cetuximab. **You may be eligible if...** - You are between 18 and 74 years old - You have confirmed head and neck cancer (mouth, throat, or voice box) that cannot be cured by surgery or radiation - Your tumor tests positive for a protein called PD-L1 - Your general health is good enough to tolerate chemotherapy - You have measurable disease on imaging **You may NOT be eligible if...** - You have previously had chemotherapy for this cancer (unless it was part of a completed treatment more than 6 months ago) - You have HIV, active hepatitis B or C - You have received prior immunotherapy (anti-PD-1 or anti-PD-L1) - You have an active autoimmune disease - You have a history of organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.